Tianeptine
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Tianeptine — ZaZa, gas station heroin — is a synthetic antidepressant of the dibenzothiazepine class. Structurally a tricyclic, it is pharmacologically distinct from classical tricyclics like imipramine. Tianeptine is a full mu-opioid receptor agonist,[1] producing its effects by activating opioid signaling on inhibitory neurons in the hippocampus.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, oxycodone, hydrocodone +4 moremorphine, oxycodone, hydrocodone, heroin, tramadol, codeine, fentanyl show less
Synthesized around 1970 by the French Society of Medical Research, tianeptine entered clinical use in France by 1983 under the trade name Stablon. For three decades it was mischaracterized as a "serotonin reuptake enhancer" until a 2014 study identified it as a μ-opioid agonist,[1] fundamentally revising the mechanistic understanding. It is prescribed in approximately 66 countries but remains unapproved in the United States, where it circulates as an unregulated supplement.
Subjective effects include anxiolysis, mood elevation, sedation, and euphoria. At therapeutic doses the experience is a quiet lifting of distress without sedation or cognitive fog — closer to background mood correction than any recognizable opioid state. At supratherapeutic doses, opioid-pattern effects dominate: heavy sedation, respiratory slowing, and nausea.[3]
Tianeptine is cardiovascularly safe at therapeutic doses[4] but produces severe opioid-type physical dependence and respiratory depression at supratherapeutic doses.[3] The ultra-short half-life drives interdosing withdrawal that accelerates dose escalation from milligrams to grams within weeks; one confirmed fatality involved combined use with alcohol.[5] Clinical use is well-characterized across decades of prescription data, though whether opioid agonism fully accounts for antidepressant efficacy remains unresolved.[6]
History[edit]
Discovery
Tianeptine was synthesized around 1970 by the French Society of Medical Research, with a patent filed in 1971. The compound entered clinical use in France under the trade name Stablon around 1983, with full marketing by Laboratoires Servier by 1989.[7] It was initially characterized as a "serotonin reuptake enhancer" — a pharmacologically unusual framing that contradicted the prevailing monoamine hypothesis of depression and generated decades of scientific interest.[8]
Scientific Significance
Through the 1990s, tianeptine became a key tool compound in stress neurobiology. Bruce McEwen's group at Rockefeller University demonstrated that it prevents and reverses stress-induced dendritic atrophy in hippocampal neurons — effects that fluoxetine and desipramine failed to replicate.[9][10] In 2014, Gassaway, Javitch, and Sames at Columbia University published the landmark finding that tianeptine is a full mu-opioid receptor agonist,[1] fundamentally revising the mechanistic understanding and raising new questions about its abuse liability.
Emergence as a Drug of Abuse
Tianeptine entered the US recreational market through dietary supplement loopholes, sold at gas stations under brand names including "Tianaa," "ZaZa," and "Tianna".[3] State-level scheduling began with Alabama classifying it as Schedule I in November 2021, followed by Florida's emergency scheduling in September 2023.[11] As of 2026, tianeptine remains prescribed in approximately 66 countries but is unapproved in the United States, United Kingdom, Canada, and Australia.[7]
The name tianeptine derives from its chemical structure — the thiazepine ring system with an amino side chain. In US drug culture, the compound is most widely known as "ZaZa" or "gas station heroin," names reflecting both its commercial branding and its opioid-like effects at high doses. The colloquial framing captures the paradox of a prescription antidepressant sold alongside energy drinks and vape cartridges — an image that has driven both media attention and legislative action.
Chemistry[edit]
Structural Class
Tianeptine is a dibenzothiazepine derivative — a modified tricyclic compound with a sulfonyl-bridged benzo[c][2,1]benzothiazepine core and a heptanoic acid side chain. Despite the tricyclic scaffold, it lacks the anticholinergic, antihistaminic, and alpha-adrenergic blocking properties of classical tricyclic antidepressants like imipramine and amitriptyline.
The core structure consists of two benzene rings bridged by a seven-membered thiazepine ring containing a sulfonyl group (SO₂) and an amine nitrogen. A chlorine substituent sits at position 3, a methyl group at position 6. The heptanoic acid side chain extends from position 11 through a secondary amine linkage, terminating in a carboxylic acid group critical to the compound's beta-oxidation metabolic pathway.
The chemical class has been erroneously described as "benzamide" in some databases. Tianeptine contains no benzamide moiety; its structure is confirmed as dibenzothiazepine.[6]
Molecular Properties
| Molecular formula | C₂₁H₂₅ClN₂O₄S |
| Molecular weight | 437.0 g/mol |
Stereochemistry
Tianeptine has one stereocenter at position 11 of the thiazepine ring. The enantiomers have been separated using chirality HPLC, and absolute configurations assigned by vibrational circular dichroism spectroscopy.[12] The S-enantiomer shows higher protein binding affinity. Differential pharmacological effects of the individual enantiomers remain uncharacterized in vivo; the drug is administered as the racemic mixture.[12]
Salt Forms
Tianeptine is commercially available as the sodium salt (Stablon — the most widely prescribed form), the free acid, and the sulfate salt. The sodium salt is formulated as immediate-release 12.5 mg tablets dosed three times daily. The sulfate salt has appeared in US dietary supplement products.
Pharmacology[edit]
Mechanism of Action
Primary Target: Mu-Opioid Receptor
Tianeptine is a full agonist at the μ-opioid (MOR), the molecular target underlying both its antidepressant effects and its abuse potential.[1] It binds MOR with moderate affinity and shows minimal activity at the δ-opioid and no activity at the κ-opioid.[1]
The antidepressant effect depends entirely on MOR. Studies in MOR-knockout mice show complete loss of antidepressant activity.[13] More precisely, the effect requires MOR expression on somatostatin-positive inhibitory neurons in the ventral hippocampus; deleting MOR from these neurons abolishes both acute and chronic antidepressant responses.[2]
Unlike fluoxetine, tianeptine does not promote hippocampal neurogenesis, indicating a mechanistically distinct antidepressant pathway.[2][13]
AMPA Receptor Potentiation
Tianeptine strengthens AMPA signaling indirectly through postsynaptic kinase cascades involving CaMKII and PKA.[14] This is not direct receptor binding but a downstream amplification of glutamate transmission.
The effect is region-specific: AMPA and NMDA currents increase in the hippocampus while NMDA currents decrease in the amygdala[15] — a pattern that may explain simultaneous cognitive and anxiolytic benefits.
Superseded Hypothesis
For three decades, tianeptine was described as a "serotonin reuptake enhancer".[8] The 2014 MOR agonism discovery[1] and subsequent research established that the mechanism operates independently of serotonin receptor or transporter activity.[6]
Pharmacokinetics
Tianeptine is nearly completely absorbed after oral dosing (~99% bioavailability) with no significant first-pass metabolism.[16][17] Peak blood levels are reached in under an hour. The half-life is short at approximately 2.5 hours, requiring three-times-daily dosing in the standard regimen.
The drug is metabolized primarily through beta-oxidation of its heptanoic acid side chain — a pathway analogous to fatty acid metabolism rather than the liver CYP450 system used by most antidepressants.[8] This confers a low risk of drug interactions through enzyme competition, a clinically relevant advantage for patients on multiple medications.
The principal active metabolite, MC5, has a longer half-life of approximately 7 hours and retains MOR-dependent activity.[13] MC5 likely contributes to sustained antidepressant effects between doses of the short-lived parent compound.
Neuroscience[edit]
Where It Acts
Tianeptine's antidepressant action is localized to a specific inhibitory neuron population in the ventral hippocampus — somatostatin-positive GABAergic interneurons that gate hippocampal output to mood-regulating circuits.[2] Deleting mu-opioid receptors from these neurons abolishes the antidepressant effect entirely. This is mechanistically distinct from SSRIs, which engage serotonergic neurogenesis pathways.[13]
At supratherapeutic doses, tianeptine recruits the classical mesolimbic pathway — ventral tegmental area to nucleus accumbens — producing the euphoria and reinforcement characteristic of opioid agonists.[3]
Why It Matters
Tianeptine provides the strongest evidence that mu-opioid receptor activation on specific interneuron populations can produce antidepressant effects independent of serotonin modulation. It also prevents and reverses stress-induced shrinkage of hippocampal neurons,[9][10] promotes new synaptic connections,[18] and suppresses neuroinflammation by dampening microglial pro-inflammatory signaling.[19][20]
These converging actions — opioid circuit modulation, structural neuroprotection, and anti-inflammatory effects — position tianeptine at the intersection of three major theoretical frameworks for understanding how antidepressants work.
Key unresolved questions include whether MOR agonism alone fully explains tianeptine's antidepressant efficacy or whether the AMPA/glutamate pathway operates as an independent parallel mechanism.[6] The pharmacological basis for the sharp transition between a well-tolerated antidepressant at therapeutic doses and a compulsively used opioid at supratherapeutic doses remains unexplained by simple dose-response scaling.
Subjective Effects[edit]
Tianeptine's experiential character splits sharply by dose context. At prescribed doses for depression, the effect is subtle and functional — a background reduction in distress and anxiety without recognizable opioid qualities. The opioid phenomenology emerges only at doses far above the therapeutic range, where sufficient μ-opioid occupancy generates classical warmth, euphoria, and sedation.[1] Set and setting exert outsized influence: the same compound functions as a clinical antidepressant in prescription contexts and as a compulsively redosed euphoriant in recreational ones.
Among opioid agonists, supratherapeutic tianeptine is most comparable to tramadol — a moderate, short-acting opioid warmth with pronounced anxiolysis. Tianeptine's near-complete oral bioavailability and ultra-short half-life create a distinctly compressed experience cycle that sets it apart from longer-acting opioids.[16]
Effect Grid
At common doses (25–50 mg oral, single dose), anxiolysis becomes more pronounced and mood elevation is clearly perceptible. Motivation enhancement and a sense of emotional warmth emerge. Cognitive effects remain neutral to mildly positive — tianeptine was superior to escitalopram on cognitive measures in clinical trials at this therapeutic range.
Physically, mild stimulation may be noted. Constipation and nausea are possible but uncommon. No cardiovascular changes. Duration remains approximately 2–4 hours, with the MC5 metabolite contributing to a subtle tail of residual effects.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tactile euphoria · Muscle relaxation · Nausea · Constipation · Sedation · Insomnia · Restlessness · Bodily heaviness · Physical fatigue · Dizziness · Excessive sweating · Muscle tension · Stimulation · Spontaneous body sensations · Headache · Yawning · Watery eyes · Trembling · Diarrhea · Brain zaps · Dry mouth · Sexual arousal suppression · Appetite suppression · Vomiting · Motor control impairment · Tingling / electric sensations · Pain enhancement
Constipation · Sedation · Insomnia · Restlessness · Bodily heaviness · Physical fatigue · Dizziness · Excessive sweating · Muscle tension · Stimulation · Spontaneous body sensations · Headache · Yawning · Watery eyes · Trembling · Diarrhea · Brain zaps · Dry mouth · Sexual arousal suppression · Appetite suppression · Vomiting · Tingling / electric sensations · Pain enhancement
Motivation suppression · Motivation enhancement · Cognitive impairment · Focus enhancement · Focus suppression · Thought deceleration · Confusion · Information processing suppression · Thought acceleration · Thought disorganization · Memory suppression
Focus suppression · Thought deceleration · Confusion · Information processing suppression · Thought acceleration · Thought disorganization · Memory suppression
Anhedonia · Dysphoria · Emotional suppression
Depersonalization · Disinhibition
Timeline
First perceptible effects emerge as a subtle shift in background mood and a mild reduction in anxiety. Physically unremarkable.
Anxiolysis and mood elevation build toward peak intensity. At supratherapeutic doses, warmth and the first hints of opioid-like euphoria become apparent.
Maximum subjective intensity coinciding with Tmax (~56 minutes post-ingestion). Anxiolysis, mood elevation, and at higher doses euphoria and muscle relaxation are at their strongest. Cognitive function preserved at therapeutic doses.
Effects decline in parallel with the short elimination half-life (~2. 5 hours). At supratherapeutic doses, interdosing withdrawal cues may emerge during this phase, driving compulsive redosing.
Residual anxiolysis and subtle mood effects persist, likely mediated by the MC5 metabolite (t1/2 ~7. 2 hours). Functional impairment is minimal at therapeutic doses.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · oxycodone · hydrocodone
Toxicity
Acute Toxicity
No human lethal dose has been established. At the standard therapeutic dose of 37.5 mg/day (12.5 mg three times daily), tianeptine has a favorable safety profile with no dose-limiting organ toxicity.
At supratherapeutic doses (1–10 g/day documented in abuse cases), tianeptine produces an opioid overdose pattern: deep sedation, respiratory depression, and loss of consciousness.[3] These effects are partially or fully reversible with naloxone.[3]
One confirmed fatality involved a 26-year-old male with co-ingested alcohol.[5] A 2025 systematic review notes increasing fatal outcomes associated with tianeptine misuse.[21]
Cardiovascular Safety
Tianeptine does not affect heart rate, blood pressure, or cardiac conduction at therapeutic doses.[4] In clinical populations exceeding 3,300 patients, cardiovascular safety was maintained over up to one year, with fewer cases of drops in blood pressure on standing than comparator antidepressants.[22][23] This profile contrasts sharply with classical tricyclics.
Liver Toxicity
Liver damage is rare. No dose adjustment is required for liver impairment or alcoholism.[8]
Neonatal Exposure
Tianeptine crosses the placenta. A documented case of severe neonatal opioid withdrawal required treatment with oral morphine after phenobarbital failed.[24] Tianeptine is not detected by routine urine drug screens, creating diagnostic challenges when infants present with unexplained withdrawal symptoms.
Diagnostic Challenge
Tianeptine does not appear on standard opioid immunoassay urine drug screens.[24] Specialized laboratory testing is required for confirmation. In emergency settings, this means a patient presenting with opioid overdose symptoms may test negative on standard screening — a critical diagnostic gap.
Psychological Risks
Published case reports describe clinical courses consistent with opioid use disorder: compulsive use despite deteriorating health and circumstances, preoccupation with obtaining supply, and continued use despite negative consequences.[25] The anxiolytic effect has been identified as a primary driver of initial use escalation.[26]
No reports of tianeptine-induced psychosis or psychiatric destabilization at therapeutic doses have been identified. Changes in dreaming have been reported as a side effect.[8]
Tolerance and Dependence
At the standard dose of 37.5 mg/day, tianeptine was described as having low abuse potential in early clinical reviews.[8] Animal models show no tolerance or withdrawal at clinically relevant doses.[27]
At abuse doses, the dependence profile is severe and opioid-like:
- Rapid tolerance: Users escalate from therapeutic doses to grams per day within weeks to months[3]
- Physical dependence: Opioid-type withdrawal syndrome with onset consistent with the 2.5-hour half-life[28][25]
- Withdrawal symptoms: anxiety, agitation, nausea, vomiting, diarrhea, sweating, muscle pain, and cravings — identical to opioid withdrawal[28]
- Clinical course: Consistent with opioid use disorder diagnosis[25]
The short half-life drives a cycle of interdosing withdrawal that accelerates dose escalation — a pharmacokinetic trap that explains the rapid progression of tianeptine use disorder.
Buprenorphine-naloxone is first-line treatment for tianeptine withdrawal and maintenance.[25][26][29] Microdose buprenorphine induction has been described.[29] Clonidine may serve as a useful adjunct.[28] Methadone has been used in complex cases.[30] Relapse rates are high; long-term follow-up and residential treatment are recommended for severe cases.
Recovery resources, crisis lines, and support pathways → View all
Drug Interactions
Alcohol reduces tianeptine absorption by approximately 30%[16] but the combination is dangerous in overdose — the only confirmed fatal case involved tianeptine plus alcohol.[5]
Other opioid agonists produce additive sedation and respiratory depression. Concurrent Methadone and tianeptine use has been documented in complex clinical cases.[30]
Benzodiazepines and other sedatives produce additive sedation. Concurrent etizolam and tianeptine withdrawal has been documented, highlighting polysubstance complexity.[31]
Monoamine oxidase inhibitors: No published interaction data exist. Standard MAOI precautions apply with a 14-day washout period.[8]
CYP450-metabolized drugs: Tianeptine's beta-oxidation metabolism confers lower interaction risk than most antidepressants.[8] No clinically significant CYP450 interactions have been documented.
Serotonin syndrome risk is low. Tianeptine is not a significant serotonergic agent at standard doses. No serotonin syndrome cases involving tianeptine have been reported.
Contraindications
Pregnancy is an absolute contraindication. Tianeptine crosses the placenta and causes severe neonatal opioid withdrawal requiring opioid-based treatment.[24]
Concurrent opioid use carries additive respiratory depression risk. The invisibility of tianeptine on standard drug screens compounds this danger in clinical settings.
Alcohol use disorder is a relative contraindication. While alcohol reduces tianeptine absorption, the combination potentiates overdose risk — particularly in patients using supratherapeutic doses.[5]
Breathing disorders are a relative contraindication. As a μ-opioid agonist, tianeptine carries dose-dependent respiratory depression risk — negligible at therapeutic doses but relevant in patients with pre-existing respiratory compromise.
Severe kidney impairment requires dose reduction due to prolonged elimination.[17]
Harm Reduction[edit]
Forms & Identification
Tianeptine circulates in two distinct contexts: pharmaceutical tablets (12.5 mg tianeptine sodium, branded as Stablon or Coaxil) and unregulated supplement products (capsules or powders containing tianeptine sulfate or sodium in variable amounts). The pharmaceutical forms are reliably dosed. The supplement forms — sold under names like "Tianaa," "ZaZa," and "Tianna" — contain inconsistent amounts with no standardized quality control.
For unregulated products, dose verification is the primary safety concern. Without analytical testing, the amount of tianeptine per capsule or scoop is unknown. Volumetric dosing of loose powder is unreliable due to density variation between salt forms.
Guidelines
- Test unregulated products with an analytical service before use — labeled content does not guarantee actual content or dose
- Do not exceed 37.5 mg total per day (12.5 mg three times daily) — the established therapeutic ceiling
- Time doses at least 4–6 hours apart to avoid stacking
- Track daily consumption carefully — dose escalation often begins subtly and accelerates quickly
- Do not use tianeptine to manage acute emotional distress — the short half-life makes it poorly suited to crisis self-medication and creates a redosing cycle
- Keep a written log of doses and amounts — if the log shows increasing use over days or weeks, this is an early warning sign
Set & Setting
Context drives whether tianeptine use remains therapeutic or escalates toward compulsive consumption. Prescribed use within a clinical relationship, with three-times-daily dosing at 12.5 mg, rarely leads to dependence. Unsupervised use of unregulated products, especially when driven by self-medication of anxiety, carries high escalation risk.
The short duration of effects (2–4 hours) creates pressure to redose. Anyone using tianeptine outside a prescription context should be aware that the urge to take another dose shortly after effects fade is a pharmacokinetic feature of the compound, not a sign that the initial dose was insufficient.
Aftercare & integration. After discontinuing supratherapeutic tianeptine use, physical recovery takes priority. Opioid-type withdrawal typically peaks within 24–72 hours given the short half-life. Adequate hydration, rest, and nutritional support help manage acute symptoms.
Sleep disruption, anxiety, and low mood commonly persist for days to weeks after cessation. These are expected features of opioid withdrawal recovery, not signs of treatment failure. Professional support — particularly with buprenorphine-based medication — significantly improves outcomes.
Recovery & Support
Tianeptine use disorder follows opioid use disorder patterns and responds to the same evidence-based treatments. Buprenorphine-naloxone (Suboxone) is first-line medication-assisted treatment.[25] Patients should inform treatment providers that tianeptine is an opioid agonist, as many clinicians are unfamiliar with the substance.
Relapse rates are high, consistent with opioid use disorder generally. Long-term medication-assisted treatment, ongoing therapeutic support, and — for severe cases — residential treatment improve outcomes. Peer support communities and opioid recovery groups provide additional structure during maintenance.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow or stopped breathing, blue lips or fingernails, unresponsiveness to voice or touch, pinpoint pupils, or loss of consciousness after tianeptine use indicate opioid overdose. Deep sedation that does not respond to loud voice or physical stimulation requires immediate intervention.
Immediate steps:
- 1. Call emergency services immediately
- 2. Administer naloxone if available — tianeptine overdose responds to naloxone[3]
- 3. A second naloxone dose may be required given its short duration of action
- 4. Place the person in the recovery position (on their side) to prevent aspiration
- 5. Stay with the person until help arrives and monitor breathing continuously
- 6. Do not induce vomiting
What to tell the dispatcher: State that the person has taken tianeptine (an opioid agonist), the approximate amount if known, the time of last dose, and current symptoms. Note that tianeptine will not appear on standard drug screens. Good Samaritan laws in many jurisdictions protect people who call for help during an overdose.
Reversal agent: Naloxone (Narcan) reverses tianeptine overdose. Because tianeptine's effects may outlast naloxone's duration of action, the person can re-sedate after naloxone wears off — ongoing monitoring is essential.
Legal Status[edit]
The regulatory status of tianeptine varies sharply by jurisdiction, reflecting the tension between its established clinical use as a prescription antidepressant in over 60 countries and its emerging profile as a drug of abuse where it lacks pharmaceutical approval.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Not scheduled under the Controlled Substances Act | FDA consumer warning January 2024: tianeptine unlawful in food or dietary supplements. STAND Against Emerging Opioids Act proposed Schedule III classification[11] |
| Alabama | Schedule I (state) | Effective November 14, 2021[11] |
| Florida | Schedule I (state) | Emergency adoption effective September 20, 2023[11] |
| Kentucky, Michigan, Minnesota, Mississippi, Ohio | Controlled substance (state-level) | Various restrictions in place[11] |
| France | Approved prescription drug | Trade name Stablon; Laboratoires Servier; approved ~1983–1989[7] |
| European Union (~15 states) | Approved prescription drug | Available in France, Portugal, Bulgaria, Romania, Slovakia, Poland, Malta, Hungary, Lithuania, Slovenia, Czech Republic, Austria, Latvia, Estonia, Luxembourg. Trade names: Stablon, Coaxil[7] |
| United Kingdom | Not approved | Not available[7] |
| Canada | Not approved | Not available |
| Australia | Not approved | Not listed on ARTG; TGA has considered scheduling |
| Global | Varies | Marketed in 66+ countries across Europe (excluding UK, Italy), Asia (Singapore, Japan), Latin America[7] |
The US regulatory landscape is evolving rapidly. As of early 2026, tianeptine remains federally unscheduled, but the FDA's January 2024 warning and the bipartisan STAND Act represent movement toward federal control. Multiple states have enacted Schedule I or equivalent restrictions, creating a patchwork of state-level regulation.
The ongoing TNX-601 ER Phase 2 trial introduces the possibility that a US-approved pharmaceutical formulation could coexist with state-level scheduling of unregulated supplement forms.[6]
references
- [1]
- [2] ^abcdHan J, Andreu V, Langreck C, Pekarskaya EA, Grinnell SG, et al. (2022) Mu opioid receptors on hippocampal GABAergic interneurons are critical for the antidepressant effects of tianeptine — Neuropsychopharmacology doi:10.1038/s41386-021-01192-2
- [3]
- [4] ^abJuvent M, Douchamps J, Delcourt E, Kostucki W, Dulcire C, et al. (1990) Lack of cardiovascular side effects of the new tricyclic antidepressant tianeptine — Clinical Neuropharmacology PMID:2306747
- [5] ^abcdProenca P, Teixeira H, Pinheiro J, Monsanto PV, Vieira DN (2007) Fatal intoxication with tianeptine (Stablon) — Forensic Science International PMID:17630235
- [6]